News Releases

Month Year

Investor Alerts

Feb 24, 2016

Anika Therapeutics Announces $25 Million Accelerated Share Repurchase

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Feb 17, 2016

Anika Therapeutics to Present at the 2016 Canaccord Genuity Musculoskeletal Conference on March 1

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Feb 10, 2016

Anika Therapeutics to Issue Fourth-Quarter 2015 Financial Results and Business Highlights on Wednesday, February 24

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its fourth-quarter 2015 financial results after the close of the market on...
Dec 29, 2015

Anika Therapeutics, Inc. Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST® Study

Cartilage Regeneration Therapy Builds Upon Company's Orthobiologics Experience, Representing Expansion into Field of Regenerative Medicine

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Dec 9, 2015

Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA's Center for Drug Evaluation and Research

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Nov 19, 2015

Anika Therapeutics to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 1

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Nov 3, 2015

Anika Therapeutics Announces Health Canada Approval of CINGAL® for the Treatment of Pain Associated with Osteoarthritis of the Knee

Achieves First Approval for Innovative Therapy Combining Hyaluronic Acid Technology with FDA-Approved Steroid

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Oct 29, 2015

Anika Appoints Richard Hague to Role of Chief Commercial Officer

Industry Veteran to Oversee Further Global Expansion of Commercial Platform, Strengthening of Commercial Partnerships, and Development of Direct Commercial Capability

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Oct 28, 2015

Anika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015

Company Achieves 37.5% Year-over-Year Diluted EPS Growth in Quarter

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Oct 14, 2015

Anika Therapeutics to Issue Third-Quarter 2015 Financial Results and Business Highlights on Wednesday, October 28

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its third-quarter 2015 financial results after the close of the market on...
Aug 19, 2015

Anika Therapeutics, Inc. Ranked #90 on Fortune's Fastest-Growing Companies for 2015

Anika Therapeutics, Inc. Ranked #90 on Fortune's Fastest-Growing Companies for 2015
Jul 29, 2015

Anika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline Progress

Strength in Quarter Driven by Continued Adoption of Orthobiologics Products;

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported...
Jul 15, 2015

Anika Therapeutics to Issue Second Quarter 2015 Financial Results and Business Highlights on Wednesday, July 29

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its second-quarter 2015 financial results after the close of the market on...
Jul 9, 2015

Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat Injection of CINGAL for Treatment of Osteoarthritis of the Knee

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported...
Jun 23, 2015

Anika Therapeutics Files Investigational Device Exemption to Initiate Phase III Study to Expand Indication of MONOVISC® to Treat Pain Caused by Osteoarthritis of the Hip

Study to be Sponsored by Company's Exclusive U.S. Distributor and Commercial Partner, DePuy Synthes Mitek Sports Medicine

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology today announced...
Jun 17, 2015

Anika Therapeutics Announces Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst

Research Collaboration to Focus on Innovative Therapy for Rheumatoid Arthritis

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today...
May 21, 2015

Anika Therapeutics to Present at Jefferies 2015 Global Healthcare Conference on June 4

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at...
Apr 28, 2015

Anika Therapeutics CEO Dr. Charles H. Sherwood to be Honored at UMass Amherst Undergraduate Commencement Ceremony on May 8

Anika Therapeutics CEO Dr. Charles H. Sherwood to be Honored at UMass Amherst Undergraduate Commencement Ceremony on May 8
Apr 28, 2015

Anika Therapeutics Reports First-Quarter 2015 Financial Results

Product Revenue Grows 8% to $15.5 Million

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (HA) technology, today reported...
Apr 28, 2015

Anika Therapeutics Announces Presentation of Seven Abstracts at 12th Annual World Congress of the International Cartilage Repair Society

Research Demonstrates Positive Clinical Outcomes for Hyalofast®

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today announced...
Apr 17, 2015

Anika Therapeutics Reports on Cingal® 13-01 Study Clinical Trial Top Line Data and Announces the Completion of Cingal 13-02 Study's Patient Enrollment

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today announced...
Apr 15, 2015

Anika Therapeutics Announces Date of First-Quarter 2015 Financial Results Conference Call

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its first-quarter 2015 financial results after the close of the market on Tuesday,...
Apr 10, 2015

Hyalomatrix® Receives CMS Reimbursement Coverage in 11 States

BEDFORD, Mass.--(BUSINESS WIRE)-- Hyalomatrix, a unique advanced wound care device based on hyaluronic acid (HA) technology, is now eligible for reimbursement as a skin substitute through the...
Apr 8, 2015

Anika Therapeutics Files IDE Application with U.S. FDA for Hyalofast®

CE Marked Cartilage Regeneration Product Has Demonstrated Positive Outcomes Internationally

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today announced...
Mar 17, 2015

Anika Therapeutics to Present at Canaccord Genuity Musculoskeletal Conference March 24

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the 10th...

Show per page